➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Baxter
Medtronic
Harvard Business School
Dow

Last Updated: June 2, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DESOXIMETASONE

» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Desoximetasone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01018134 Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study Completed Taro Pharmaceuticals USA Phase 2 2009-11-01 The objectives of this study are to evaluate the efficacy and safety of two dosing regimens of desoximetasone 0.05% and 0.25% topical sprays as compared to a vehicle spray in patients with moderate to severe plaque psoriasis.
NCT01043393 Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study Completed Taro Pharmaceuticals USA Phase 2 2010-02-01 The objective of this study is to evaluate the potential of desoximetasone 0.25% topical spray to suppress HPA axis function. The potential for adrenal suppression will be assessed following multiple dosing with Desoximetasone 0.25% Topical Spray in patients with moderate to severe plaque psoriasis. The secondary objectives are to evaluate the efficacy parameters and to evaluate the adverse event (AE) profile.
NCT01206387 Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis Completed Taro Pharmaceuticals USA Phase 3 2010-08-01 The objective of this study is to demonstrate that desoximetasone 0.25% topical spray is effective for the treatment of patients with moderate to severe plaque psoriasis.
NCT01206660 Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis Completed Taro Pharmaceuticals USA Phase 3 2010-08-01 The objective of this study is to demonstrate that desoximetasone 0.25% topical spray is effective for the treatment of patients with moderate to severe plaque psoriasis.
NCT02340169 Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis Recruiting Taro Pharmaceuticals USA Phase 4 2015-01-01 The objective of this study is to evaluate the potential of Topicort® (desoximetasone) Topical Spray, 0.25% to suppress hypothalmic pituitary adrenal axis function. The secondary objectives are to evaluate the efficacy parameters, pharmacokinetics and adverse event profile.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Desoximetasone

Condition Name

Condition Name for Desoximetasone
Intervention Trials
Psoriasis 7
Plaque Psoriasis 1
Atopic Dermatitis 1
Scalp Psoriasis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Desoximetasone
Intervention Trials
Psoriasis 9
Eczema 1
Dermatitis, Atopic 1
Dermatitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Desoximetasone

Trials by Country

Trials by Country for Desoximetasone
Location Trials
United States 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Desoximetasone
Location Trials
South Carolina 2
New Mexico 2
Kansas 2
North Carolina 1
New Jersey 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Desoximetasone

Clinical Trial Phase

Clinical Trial Phase for Desoximetasone
Clinical Trial Phase Trials
Phase 4 4
Phase 3 3
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Desoximetasone
Clinical Trial Phase Trials
Completed 5
Active, not recruiting 2
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Desoximetasone

Sponsor Name

Sponsor Name for Desoximetasone
Sponsor Trials
Taro Pharmaceuticals USA 7
Psoriasis Treatment Center of Central New Jersey 2
Siriraj Hospital 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Desoximetasone
Sponsor Trials
Industry 7
Other 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Dow
Merck
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.